Approval · Notice of Compliance 816 · 2002
RESCULA: Notice of Compliance 816
Issued April 3, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 816
- Date
- April 3, 2002
- Company
- Novartis Ophthalmics Novartis Pharmaceuticals (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Elevated intraocular pressure therapy, docosanoid
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RESCULA | 02245525 | Cancelled Post Market |
Medicinal ingredients
- UNOPROSTONE ISOPROPYL 0.15 PER